BVS

Bioventus Inc. Class A Common Stock

$7.93 -6.82%

Recent alerts on BVS

All signals →

SEC filing BVS FDA Reclassifies Exogen to Class II, CMS Updates Billing Rules, Reiterates 2026 Guidance

News Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

News Encompass Health (EHC) Expands in Louisville With New Rehab Unit

News Compelling Reasons to Hold on to Cigna (CI) Stock for Now

News J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

News Humana (HUM) Partners With UAB to Boost Care for MA Members

News Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

News Merck (MRK) to Buy Private Ophthalmology Company EyeBio

News Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue

Insider trade Sale by Michelle Mcmurry-Heath

News Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics

SEC filing BVS Reports $157.9M Q4 Revenue, $0.21 GAAP EPS, $0.24 Adjusted EPS, $38M Cash Flow, 2026 Guidance Outlook

News Bioventus Non-GAAP EPS of $0.24 beats by $0.02, revenue of $157.9M beats by $2.95M

Short volume Short volume 67% of volume (6.5σ)

Get push alerts for BVS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS